Vol 13, No 5 (October 31, 2024): Chinese Clinical Oncology

Original Article

Real-world evidence of survival outcomes in breast cancer subtypes after neoadjuvant chemotherapy in a Brazilian reference center
Marcelo Antonini, André Mattar, Fernanda Grace Bauk Richter, Gabriel Duque Pannain, Marina Diogenes Teixeira, Andressa Gonçalves Amorim, Denise Joffily Pereira da Costa Pinheiro, Leonardo Ribeiro Soares, Francisco Pimentel Cavalcante, Marcellus do Nascimento Moreira Ramos, Marcelo Madeira, Felipe Zerwes, Odair Ferraro, Reginaldo Guedes Coelho Lopes, Luiz Henrique Gebrim
Chinese Clinical Oncology  
2024;
13
(5)
:65
.
 (31 October 2024) 
PDF Full Text (1372) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
A meta-analysis and systematic review of randomized controlled trials in combination gemcitabine with erlotinib in the pancreatic cancer
Longxiang Yan, Wenming Lu, Wenjin Huang, Alexis Bindzi Zoa, Jiang Zheng, Mingbai Qin, Jing Du, Qiuxiang Xiao, Zhiping Liu, Yuantong Tian
Chinese Clinical Oncology  
2024;
13
(5)
:66
.
 (31 October 2024) 
PDF Full Text (1318) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Short-term outcomes in obese and non-obese patients undergoing transperitoneal laparoscopic adrenalectomy for benign or malignant adrenal diseases: an updated systematic review and meta-analysis
Maurizio Zizzo, Andrea Morini, Magda Zanelli, Chiara Grasselli, Francesca Sanguedolce, Andrea Palicelli, Giuseppe Broggi, Nektarios I. Koufopoulos, Lucia Mangone, Melissa Nardecchia, Angelo Cormio, Rosario Caltabiano, Giulia Besutti, Stefano Ascani, Massimiliano Fabozzi
Chinese Clinical Oncology  
2024;
13
(5)
:67
.
 (31 October 2024) 
PDF Full Text (1336) Reporting Checklist Peer Review File COI Form Open Access Get Permission

Review Article

Primary angiosarcoma of the breast: a literature review
Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien
Chinese Clinical Oncology  
2024;
13
(5)
:68
.
 (31 October 2024) 
PDF Full Text (1910) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises—a narrative review
Valeria Internò, Assunta Melaccio, Pasquale Vitale, Roberta Spedaliere, Massimo Buonfantino, Raffaella Messina, Anna Laura Lippolis, Francesco Signorelli, Raffaele Addeo, Francesco Giuliani
Chinese Clinical Oncology  
2024;
13
(5)
:69
.
 (31 October 2024) 
PDF Full Text (1478) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Advancements in cholangiocarcinoma: evolving strategies for diagnosis, treatment, and palliation over three decades
Charbel Elias, Amaan Rahman, Jason Mial-Anthony, Godwin Packiaraj, Andrew Crane, Sarmad Alshamery, Armando Ganoza, Vikraman Gunabushanam, Colin Powers, Stalin Dharmayan, Subashini Ayloo, Hao Liu, Christof Kaltenmeier, Eishan Ashwat, Isabel Neckerman, Berkay Demirors, Michele Molinari
Chinese Clinical Oncology  
2024;
13
(5)
:70
.
 (31 October 2024) 
PDF Full Text (3304) Peer Review File COI Form Open Access Get Permission
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma
Rusi Chen, Giovanni Monaco, Bernardo Stefanini, Mariarosaria Marseglia, Stefania De Lorenzo, Francesco Tovoli
Chinese Clinical Oncology  
2024;
13
(5)
:71
.
 (31 October 2024) 
PDF Full Text (1583) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Evidence from resected early-stage non-small cell lung cancer with EGFR mutation: a literature review
Sergio Martinez-Recio, Andres Barba, Margarita Majem
Chinese Clinical Oncology  
2024;
13
(5)
:72
.
 (31 October 2024) 
PDF Full Text (2201) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Phase I trials of single-agent new drugs in head and neck cancer: a scoping review
Daria Maria Filippini, Gregoire Marret, Etienne Bastien, Raphael Sanchez, Edith Borcoman, Christophe Le Tourneau
Chinese Clinical Oncology  
2024;
13
(5)
:73
.
 (31 October 2024) 
PDF Full Text (1295) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Current status, evolution, and future perspectives in robotic platform systems for prostate cancer treatment: a narrative review
Flavia Tamborino, Guglielmo Dello Stritto, Gaetano Salzano, Peppino Lannutti, Marco Mascitti, Alessio Digiacomo, Martina Basconi, Rossella Cicchetti, Angelo Orsini, Matteo Ferro, Riccardo De Archangelis, Luigi Schips, Michele Marchioni
Chinese Clinical Oncology  
2024;
13
(5)
:74
.
 (31 October 2024) 
PDF Full Text (1183) Reporting Checklist Peer Review File COI Form Open Access Get Permission

Case Report

A case report of successful combined intra-arterial immunotherapy and cytokine genetic therapy treatment in a patient with recurrent glioblastoma
Anna V. Alyasova, Amir M. Ben Ammar, Vladimir T. Zarkua, Andrey G. Rerberg
Chinese Clinical Oncology  
2024;
13
(5)
:75
.
 (31 October 2024) 
PDF Full Text (1149) Reporting Checklist Peer Review File COI Form Open Access Get Permission

Editorial Commentary

Combination checkpoint inhibition, angiogenic inhibition and hepatic artery infusion chemotherapy for disease control of advanced hepatocellular carcinoma
Sayed Imtiaz, Mohd Raashid Sheikh
Chinese Clinical Oncology  
2024;
13
(5)
:76
.
 (31 October 2024) 
PDF Full Text (603) Peer Review File COI Form Open Access Get Permission
Triple combination of hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors for treatment of advanced hepatocellular carcinoma: more robust evidence is still needed
Mohammad Saeid Rezaee-Zavareh, Ju Dong Yang
Chinese Clinical Oncology  
2024;
13
(5)
:77
.
 (31 October 2024) 
PDF Full Text (969) Peer Review File COI Form Open Access Get Permission
The TRIPLET study: more is better?
Salim I. Khakoo
Chinese Clinical Oncology  
2024;
13
(5)
:78
.
 (31 October 2024) 
PDF Full Text (551) Peer Review File COI Form Open Access Get Permission
Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma
Sam Y. Son, Hooman Yarmohammadi
Chinese Clinical Oncology  
2024;
13
(5)
:79
.
 (31 October 2024) 
PDF Full Text (1028) Peer Review File COI Form Open Access Get Permission
Triplet regimen with camrelizumab plus apatinib in combination with hepatic artery infusion chemotherapy (HAIC): a new treatment paradigm for select patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma?
Garima Gupta, Reema Patel, Mehmet Akce, Aman Chauhan
Chinese Clinical Oncology  
2024;
13
(5)
:80
.
 (31 October 2024) 
PDF Full Text (1123) Peer Review File COI Form Open Access Get Permission